20630573

Source:http://linkedlifedata.com/resource/pubmed/id/20630573

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0205195, umls-concept:C0292818, umls-concept:C0334227, umls-concept:C0672708, umls-concept:C0740457, umls-concept:C1704419
pubmed:issue	3
pubmed:dateCreated	2010-9-13
pubmed:abstractText	To investigate the combined effect of the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) and the protease inhibitor ritonavir on renal cancer cells.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0366151
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/HIV Protease Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Hydroxamic Acids, http://linkedlifedata.com/resource/pubmed/chemical/Ritonavir, http://linkedlifedata.com/resource/pubmed/chemical/vorinostat
pubmed:status	MEDLINE
pubmed:month	Sep
pubmed:issn	1527-9995
pubmed:author	pubmed-author:AsanoTakakoT, pubmed-author:AsanoTomohikoT, pubmed-author:HoriguchiAkioA, pubmed-author:ItoKeiichiK, pubmed-author:SatoAkinoriA, pubmed-author:SumitomoMakotoM
pubmed:copyrightInfo	Copyright © 2010 Elsevier Inc. All rights reserved.
pubmed:issnType	Electronic
pubmed:volume	76
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	764.e7-13
pubmed:meshHeading	pubmed-meshheading:20630573-Antineoplastic Agents, pubmed-meshheading:20630573-Drug Screening Assays, Antitumor, pubmed-meshheading:20630573-Drug Therapy, Combination, pubmed-meshheading:20630573-HIV Protease Inhibitors, pubmed-meshheading:20630573-Hydroxamic Acids, pubmed-meshheading:20630573-Kidney Neoplasms, pubmed-meshheading:20630573-Ritonavir, pubmed-meshheading:20630573-Tumor Cells, Cultured
pubmed:year	2010
pubmed:articleTitle	Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells.
pubmed:affiliation	Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan. zenpaku@ndmc.ac.jp
pubmed:publicationType	Journal Article